Search Result

Results for "

E2F

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Early 2 Factor (E2F) (12) Androgen Receptor (1) Apoptosis (6) Bcl-2 Family (2) Biochemical Assay Reagents (2) BMX Kinase (1) c-Myc (5) Casein Kinase (1) Caspase (1) CDK (12) Checkpoint Kinase (Chk) (1) Choline Kinase (1) DNA/RNA Synthesis (4) EGFR (1) Fluorescent Dye (1) HDAC (1) Histone Methyltransferase (2) HOXA (1) HPV (1) HSP (2) MDM-2/p53 (2) Molecular Glues (2) NEKs (1) NF-κB (1) PARP (1) PROTACs (3) Reactive Oxygen Species (ROS) (1) Small Interfering RNA (siRNA) (24) STAT (1) TNF Receptor (1) Topoisomerase (2) VEGFR (1)
By Research Areas:	Cancer (25) Inflammation/Immunology (3) Neurological Disease (3)
Oligonucleotides:	Decoy ODNs (2) Rat Pre-designed siRNA Sets (8) Mouse Pre-designed siRNA Sets (8) Human Pre-designed siRNA Sets (8) siRNAs (24)

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: Early 2 Factor (E2F)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101257

YKL-5-124 Maximum Cited Publications 17 Publications Verification	CDK	Cancer
YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-153278

Q901 CDK7-IN-21	CDK DNA/RNA Synthesis c-Myc Early 2 Factor (E2F) Topoisomerase	Cancer
Q901 (CDK7-IN-21) is a selective and potent CDK7 inhibitor with an IC₅₀ of 10 nM. Q901 disrupts MYC and E2F transcription program, downregulating cell cycle control and DNA damage repair pathways. Q901 stabilizes TOP1-DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 can be used for the research of cancer, such as colon cancer and lung cancer .

HY-16667

HLM006474 5+ Cited Publications	Early 2 Factor (E2F)	Cancer
HLM006474 is a pan *E2F* inhibitor, which inhibits E2F4 DNA-binding with an IC₅₀ of 29.8 μM in A375 cells.

HY-164827

CDK2 degrader 3	Molecular Glues CDK	Cancer
CDK2 degrader 3 is a selective *CDK2* molecular glue-like degrader. CDK2 degrader 3 induces G1 cell cycle arrest in CCNE1-amplified cancer cells. CDK2 degrader 3 is applicable to breast cancer-related research .

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-137849

RK-582	PARP	Cancer
RK-582 is a tankyrase inhibitor, antitumor agent, and orally bioavailable growth inhibitor, with an IC₅₀ of 36.1 nM against human tankyrase-1 and an IC₅₀ of 39.2 nM against human *tankyrase-2. In APC-mutated colorectal cancer cells, the sensitivity to RK-582 correlates with the level of active β-catenin*, while drug resistance associates with PIK3CA mutation. RK-582 can be used for the research of colorectal cancer ^[2].

HY-153916

TCRS-417 1 Publications Verification T417	HOXA DNA/RNA Synthesis NEKs	Neurological Disease Inflammation/Immunology Cancer
TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC₅₀ = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin (HY-17393)-resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, *NEK2, and E2F2* in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells ^[2] .

HY-149209

LL-K8-22	PROTACs CDK STAT Early 2 Factor (E2F)	Cancer
LL-K8-22 is a potent, selective and durable PROTAC CDK8-cyclin C dual degrader, with DC₅₀ values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research. (Pink: Ligand for target protein (HY-168683); Black: Linker (HY-Y0340); Blue: Ligand for E3 ligase (HY-N2427)) .

HY-101257B

YKL-5-124 TFA Maximum Cited Publications 17 Publications Verification	CDK	Cancer
YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-175729

Cyclin A/B RxL-IN-1	CDK	Cancer
Cyclin A/B RxL-IN-1 is a inhibitor targeting the Cyclin A/B RxL interaction at the hydrophobic patch (HP). Cyclin A/B RxL-IN-1 inhibits Cyclin A with an IC₅₀ of 0.12 μM. Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy in mouse cell line-derived xenograft (CDX) models. CDK-IN-19 can be used for the study of E2F-driven cancers such as small-cell lung cancer (SCLC) .

HY-159728

PROTAC PRMT3 degrader 1	PROTACs Histone Methyltransferase Apoptosis Early 2 Factor (E2F) c-Myc	Cancer
PROTAC PRMT3 degrader 1 is a selective PRMT3 PROTAC degrader with a DC₅₀ of 2.566 μM. PROTAC PRMT3 degrader 1 forms a ternary complex with MDM2 E3 ubiquitin ligase to induce proteasomal and neddylation-dependent degradation of PRMT3. PROTAC PRMT3 degrader 1 activates intrinsic apoptosis, endoplasmic reticulum stress signaling pathways. PROTAC PRMT3 degrader 1 downregulates *E2F, MYC, oxidative phosphorylation pathways. PROTAC PRMT3 degrader 1 reduces cellular asymmetric dimethylarginine (ADMA*) levels. PROTAC PRMT3 degrader 1 inhibits acute leukemia cell growth. PROTAC PRMT3 degrader 1 acts with glycolysis inhibitor 2-DG to reduce ATP production, induce intrinsic apoptosis, drive synergistic antiproliferative effects. PROTAC PRMT3 degrader 1 can be used for the research of acute leukemia .

HY-117857

MRT00033659	Casein Kinase Checkpoint Kinase (Chk) MDM-2/p53 Early 2 Factor (E2F)	Cancer
MRT00033659 is a potent broad-spectrum kinase inhibitor of CK1 (IC₅₀=0.9 μM for CK1δ) and CHK1 (IC₅₀=0.23 μM). MRT00033659, a pyrazolo-pyridine analogue, induces p53 pathway activation and E2F-1 destabilisation .

HY-142076A

CDK4/6-IN-15 hydrochloride	CDK	Cancer
CDK4/6-IN-15 hydrochloride is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 hydrochloride potently inhibits cancer cells growth. CDK4/6-IN-15 hydrochloride arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-150109A

Purinostat	HDAC	Cancer
Purinostat is a selective inhibitor of HDAC I/IIb with anti-leukemic activity. Purinostat mesylate (HY-150109), the mesylate salt of Purinostat, inhibits the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDAC I/IIb to inhibit several important factors for leukemic stem cell (LSC) survival, including c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Purinostat mesylate increases glutamate metabolism in LSC by increasing GLS1 .

HY-175397

Dth DFHBI-thalidomide	PROTACs NF-κB Early 2 Factor (E2F) Bcl-2 Family VEGFR	Cancer
Dth (DFHBI-thalidomide) is an RNA aptamer-based PROTAC degrader. Dth can degrade a variety of endogenous proteins (such as mCherry, p50, p65 and *E2F1) by replacing the 3′ module on the RNA scaffold with the RNA aptamer corresponding to the target protein. Dth upregulates IκB-α* and Bax, and downregulates *Bcl-2* and VEGF. Dth generates green fluorescence upon binding to the Broccoli RNA aptamer, enabling the tracing of RNA scaffolds. Dth can be used in cancer-related research .

HY-168996

LA-CB1	CDK Apoptosis	Cancer
LA-CB1 is an Abemaciclib (HY-16297A) derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC₅₀ of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer .

HY-162384

EPIC-0628	Histone Methyltransferase	Cancer
EPIC-0628 is an inhibitor of the *HOTAIR-EZH2* interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .

HY-153278A

Q901 TFA CDK7-IN-21 TFA	CDK DNA/RNA Synthesis c-Myc Early 2 Factor (E2F) Topoisomerase	Cancer
Q901 (CDK7-IN-21) TFA is a selective and potent CDK7 inhibitor with an IC₅₀ of 10 nM. Q901 TFA disrupts MYC and E2F transcription program, downregulating cell cycle control and DNA damage repair pathways. Q901 TFA stabilizes TOP1-DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 TFA can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 TFA can be used for the research of cancer, such as colon cancer and lung cancer .

HY-RS04112

E2F3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F3 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F3 Human Pre-designed siRNA Set A E2F3 Human Pre-designed siRNA Set A

HY-RS04110

E2F1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F1 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F1 Human Pre-designed siRNA Set A E2F1 Human Pre-designed siRNA Set A

HY-177627

Edifoligide CGT 003	Early 2 Factor (E2F)	Inflammation/Immunology
Edifoligide is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure

HY-177627A

Edifoligide sodium CGT 003 sodium	Early 2 Factor (E2F)	Inflammation/Immunology
Edifoligide sodium is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure

HY-146033

HPV18-IN-1	HPV	Cancer
HPV18-IN-1 (Compound H1) is a potent inhibitor of HPV18. HPV18-IN-1 prevents cervical cancer cells from premature cell procession and abnormal proliferation. HPV18-IN-1 supresses E7-Rb-E2F cellular pathway and DNA methylation. HPV18-IN-1 has the potential for the research of cancer diseases .

HY-170820

XYD049	Molecular Glues Bcl-2 Family CDK EGFR HSP Androgen Receptor c-Myc	Cancer
XYD049 is a CRBN-based molecular glue degrader targeting GSPT1, with a DC₅₀ of 19 nM. XYD049 mediates the formation of a ternary complex between CRBN and GSPT1, thereby triggering CRBN- and proteasome-dependent degradation of GSPT1. By degrading GSPT1, XYD049 downregulates castration-resistant prostate cancer (CRPC)-related oncogenes, including *BCL2, CDK2, E2F3, EGFR, HSP90B1, TMPRSS2, AR, AR-V7, PSA* and c-Myc. XYD049 inhibits cancer cell growth and suppresses tumor growth in mice. XYD049 can be used for research on castration-resistant prostate cancer. XYD049 consists of a linker (black part) NH2-C5-NH-Boc (HY-W004710), a CRBN-based E3 ligase ligand (blue part) Thalidomide 4-fluoride (HY-41547), and a target protein ligand (red part) GSPT1 ligand-1 (HY-170821), among which the E3 ligase ligand plus linker forms the conjugate E3 Ligase Ligand-linker Conjugate 158 (HY-170822) .

HY-RS22149

E2f8 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f8 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f8 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f8 Mouse Pre-designed siRNA Set A E2f8 Mouse Pre-designed siRNA Set A

HY-RS04115

E2F6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F6 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F6 Human Pre-designed siRNA Set A E2F6 Human Pre-designed siRNA Set A

HY-RS25812

E2f2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f2 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f2 Rat Pre-designed siRNA Set A E2f2 Rat Pre-designed siRNA Set A

HY-RS20270

E2f6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f6 Mouse Pre-designed siRNA Set A E2f6 Mouse Pre-designed siRNA Set A

HY-RS04113

E2F4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F4 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F4 Human Pre-designed siRNA Set A E2F4 Human Pre-designed siRNA Set A

HY-RS04111

E2F2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F2 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F2 Human Pre-designed siRNA Set A E2F2 Human Pre-designed siRNA Set A

HY-RS19321

E2f2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f2 Mouse Pre-designed siRNA Set A E2f2 Mouse Pre-designed siRNA Set A

HY-RS17052

E2f1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f1 Mouse Pre-designed siRNA Set A E2f1 Mouse Pre-designed siRNA Set A

HY-RS18033

E2f4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f4 Mouse Pre-designed siRNA Set A E2f4 Mouse Pre-designed siRNA Set A

HY-RS04114

E2F5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F5 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F5 Human Pre-designed siRNA Set A E2F5 Human Pre-designed siRNA Set A

HY-RS04116

E2F7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F7 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F7 Human Pre-designed siRNA Set A E2F7 Human Pre-designed siRNA Set A

HY-164184

Ly101-4B	Apoptosis Caspase HSP Early 2 Factor (E2F) DNA/RNA Synthesis	Cancer
Ly101-4B is an apoptosis inducer and multi-target inhibitor with antiproliferative, antitumor and cycytotoxic effects. Ly101-4B reduces HSF1 expression, inhibits microRNA-214 synthesis, downregulates HSP27, HSP70 and HSP90 expression, while suppressing *E2F*-dependent transcriptional activity and downregulating its target genes. Ly101-4B induces caspase 3/7-mediated apoptosis by reducing DNA synthesis, inhibiting the cell cycle and G1/S phase transition, without affecting RNA synthesis or inducing necrosis. Ly101-4B is selective for pancreatic ductal adenocarcinoma cells with different genotypes and varying degrees of E2F dependence. Ly101-4B can be used in research related to epithelial ovarian cancer and pancreatic ductal adenocarcinoma ^[2] .

HY-182241

JR4-187	c-Myc Early 2 Factor (E2F) TNF Receptor MDM-2/p53 Reactive Oxygen Species (ROS) Apoptosis	Cancer
JR4-187 is an orally active, copper-dependent anticancer agent. JR4-187 downregulates genes involved in oxidative phosphorylation, MYC targets and *E2F* targets in cancer cells, while upregulates genes involved in the TNF-α signaling pathway, p53 pathway and KRAS signaling pathway, and downregulates CTR1 protein . JR4-187 induces ROS production, apoptosis, copper-dependent cytotoxicity, and exhibits selective cytotoxicity against KRAS-mutant cancer cells. JR4-187 is well tolerated in mouse models of pancreatic cancer. JR4-187 can be used in research related to cancers such as pancreatic ductal adenocarcinoma, colon cancer and rectal cancer ^[2].

HY-RS25416

E2f7 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f7 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f7 Rat Pre-designed siRNA Set A E2f7 Rat Pre-designed siRNA Set A

HY-RS26778

E2f6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f6 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f6 Rat Pre-designed siRNA Set A E2f6 Rat Pre-designed siRNA Set A

HY-RS24507

E2f4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f4 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f4 Rat Pre-designed siRNA Set A E2f4 Rat Pre-designed siRNA Set A

HY-RS18926

E2f7 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f7 Mouse Pre-designed siRNA Set A E2f7 Mouse Pre-designed siRNA Set A

HY-RS20723

E2f5 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f5 Mouse Pre-designed siRNA Set A E2f5 Mouse Pre-designed siRNA Set A

HY-RS23496

E2f1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f1 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f1 Rat Pre-designed siRNA Set A E2f1 Rat Pre-designed siRNA Set A

HY-RS25813

E2f3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f3 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f3 Rat Pre-designed siRNA Set A E2f3 Rat Pre-designed siRNA Set A

HY-RS28670

E2f8 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f8 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f8 Rat Pre-designed siRNA Set A E2f8 Rat Pre-designed siRNA Set A

HY-RS27235

E2f5 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f5 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f5 Rat Pre-designed siRNA Set A E2f5 Rat Pre-designed siRNA Set A

HY-RS04117

E2F8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2F8 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F8 Human Pre-designed siRNA Set A E2F8 Human Pre-designed siRNA Set A

HY-RS19322

E2f3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
E2f3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2f3 Mouse Pre-designed siRNA Set A E2f3 Mouse Pre-designed siRNA Set A

HY-183118

CID-078	CDK Apoptosis	Neurological Disease Cancer
CID-078 is an orally active macrocyclic cyclin A and cyclin B inhibitor. CID-078 binds cyclin hydrophobic patches, disrupting interactions of cyclin A-Cdk2 with E2F1 and cyclin B-Cdk1 with Myt1, and selectively targets RxL binding motifs to block complex-substrate interactions. CID-078 induces DNA damage, G2/M cell cycle arrest, apoptosis, mitotic catastrophe, spindle assembly checkpoint activation, and neomorphic cyclin B-CDK2 complex formation, driving synthetic lethality in E2F-driven cancer cells. CID-078 can be used for the research of small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, advanced solid tumors, luminal HR ⁺/HER ^2- breast cancer, RB1-altered solid tumors, and neuroblastoma ^[2] .

HY-E71195

15-Hydroxyprostaglandin dehydrogenase (NAD+)	Biochemical Assay Reagents	Others
15-Hydroxyprostaglandin dehydrogenase (NAD+) (EC 1.1.1.141) acts on prostaglandin E2, F2α and B1, but not on prostaglandin D2.

Cat. No.	Product Name

HY-L201

Cell Proliferation Compound Library

3,367 compounds

Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.

MCE collects 3,367 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Species:	Human (2)
Tag:	His (1) Strep (1) Tag Free (1)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P79451

	UbcH7/UBE2L3 Protein, Human 1 Publications Verification Ubiquitin-conjugating enzyme E2 L3; UBE2L3; E2 ubiquitin-conjugating enzyme L3; L-UBC; UbcH7; Ubiquitin carrier protein L3; Ubiquitin-conjugating enzyme E2-F1; Ubiquitin-protein ligase L3; UBCE7	Human	E. coli
	UbcH7/UBE2L3 is a unique ubiquitin-conjugating E2 enzyme that cooperates with HECT-type and RBR family E3 ligases and lacks intrinsic E3-independent reactivity with lysine. It uniquely works with RBR family E3 enzymes such as PRKN, RNF31 and ARIH1, acting like a RING-HECT hybrid. UbcH7/UBE2L3 Protein, Human is the recombinant human-derived UbcH7/UBE2L3 protein, expressed by E. coli , with tag free.

HY-P701348

	UbcH7/UBE2L3 Protein, Human (sf9, His, StrepⅡ) UBE2L3; Ubiquitin-conjugating enzyme E2 L3; E2 ubiquitin-conjugating enzyme L3; L-UBC; UbcH7; Ubiquitin carrier protein L3; Ubiquitin-conjugating enzyme E2-F1; Ubiquitin-protein ligase L3	Human	Sf9 insect cells
	UbcH7/UBE2L3 is a unique ubiquitin-conjugating E2 enzyme that cooperates with HECT-type and RBR family E3 ligases and lacks intrinsic E3-independent reactivity with lysine. It uniquely works with RBR family E3 enzymes such as PRKN, RNF31 and ARIH1, acting like a RING-HECT hybrid. UbcH7/UBE2L3 Protein, Human (sf9, His, Strep) is the recombinant human-derived UbcH7/UBE2L3 protein, expressed by sf9 insect cells , with N-Strep, N-8*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (5) Rabbit (12)
Reactivity:	Human (17) Rat (9) Mouse (11)
Application:	IHC-P (8) ICC/IF (11) IF-Tissue (1) IP (6) IHC-F (1) WB (16) FC (7) ELISA (4)
Isotype:	IgG (11) IgG1 (3) IgG/Kappa (1)
Conjugation:	Non-conjugated (17)
Clonality:	Monoclonal (13) Monoclonal Antibody (1) Recombinant (8)
Modification:	Unmodified (14)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82929

	E2F2 Antibody (YA2674) DE2F2; E2F transcription factor 2; E2F-2; Transcription factor E2F2	WB, FC	Human, Mouse, Rat
	E2F2 Antibody (YA2674) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F2.

HY-P85613

	E2F-1 Antibody (YA5305) Dmel\CG6376; Dmel_CG6376; drosE2F1; E; Sev-CycE; 3A; E; var; 3-93E; E2-promoter binding facto; E2F 1; E2F transcription factor 1; E2F-1; E2F-PA; E2F-PB; E2F-PC; E2F1; E2F1 E2F transcription factor 1; E2F1_HUMAN; Evar; 3; 164; KIAA4009; l; 3; 07172; l; 3; j3B1; l; 3; j3C2; l; 3; rM729; mKIAA4009; OTTHUMP00000030661; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1.	WB, ICC/IF, IP	Human, Rat
	E2F-1 Antibody (YA5305) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to E2F-1.

HY-P85616

	EIF2S1 Antibody (YA5308) Dmel\CG6376; Dmel_CG6376; drosE2F1; E; Sev-CycE; 3A; E; var; 3-93E; E2-promoter binding facto; E2F 1; E2F transcription factor 1; E2F-1; E2F-PA; E2F-PB; E2F-PC; E2F1; E2F1 E2F transcription factor 1; E2F1_HUMAN; Evar; 3; 164; KIAA4009; l; 3; 07172; l; 3; j3B1; l; 3; j3C2; l; 3; rM729; mKIAA4009; OTTHUMP00000030661; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1.	WB, ICC/IF, IP	Human, Mouse, Rat
	EIF2S1 Antibody (YA5308) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to EIF2S1.

HY-P83021

	DP1 Antibody (YA2766) TFDP1; DP1; Transcription factor Dp-1; DRTF1-polypeptide 1; DRTF1; E2F dimerization partner 1	WB, FC	Human, Mouse, Rat
	DP1 Antibody (YA2766) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DP1.

HY-P86583

	SUZ12 Antibody (YA6275) SUZ12; CHET9; JJAZ1; KIAA0160; Polycomb protein SUZ12; Chromatin precipitated E2F target 9 protein; ChET 9 protein; Joined to JAZF1 protein; Suppressor of zeste 12 protein homolog	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	SUZ12 Antibody (YA6275) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SUZ12.

HY-P83440

	SUZ12 Antibody (YA3185) SUZ12; CHET9; JJAZ1; KIAA0160; Polycomb protein SUZ12; Chromatin precipitated E2F target 9 protein; ChET 9 protein; Joined to JAZF1 protein; Suppressor of zeste 12 protein homolog	WB, ICC/IF, IP	Human, Mouse, Rat
	SUZ12 Antibody (YA3185) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SUZ12.

HY-P85378

	SUZ12 Antibody (YA5070) SUZ12; CHET9; JJAZ1; KIAA0160; Polycomb protein SUZ12; Chromatin precipitated E2F target 9 protein; ChET 9 protein; Joined to JAZF1 protein; Suppressor of zeste 12 protein homolog	ICC/IF	Human
	SUZ12 Antibody (YA5070) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SUZ12.

HY-P82026

	E2F6 Antibody (YA1771) E2F6; Transcription factor E2F6; E2F-6	WB, ICC/IF, FC	Human
	E2F6 Antibody (YA1771) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F6.

HY-P82983

	E2F4 Antibody (YA2728) E2F4; Transcription factor E2F4; E2F-4	WB	Human
	E2F4 Antibody (YA2728) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F4.

HY-P82983A

	E2F4 Antibody (YA2728)(PBS only) E2F4; Transcription factor E2F4; E2F-4	WB	Human
	E2F4 Antibody (YA2728) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F4.

HY-P86428

	E2F-1 Antibody (YA6120) E2F1; RBBP3; Transcription factor E2F1; E2F-1; PBR3; Retinoblastoma-associated protein 1; RBAP-1; Retinoblastoma-binding protein 3; RBBP-3; pRB-binding protein E2F-1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	E2F-1 Antibody (YA6120) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F-1.

HY-P84456

	E2F-1 Antibody (YA4153) RBP3; E2F-1; RBAP1; RBBP3	WB, IHC-P, FC, ELISA	Human, Mouse
	E2F-1 Antibody (YA4153) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to E2F-1.

HY-P84456A

	E2F-1 Antibody (YA4153)(PBS only) RBP3; E2F-1; RBAP1; RBBP3	WB, IHC-P, FC, ELISA	Human, Mouse
	E2F-1 Antibody (YA4153) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to E2F-1.

HY-P80491

	E2F-1 Antibody (YA471)	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	E2F-1 Antibody (YA471) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F-1.

HY-P87593

	E2F4 Antibody (YA7277)	WB, IHC-P, IHC-F, IF-Tissue, FC, ICC/IF	Human
	E2F4 Antibody (YA7277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F4.

HY-P83558

	Ubiquitin Conjugating Enzyme E2 L3 Antibody (YA3303) E2-F1; L-UBC; UBCH7; UbcM4	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Ubiquitin Conjugating Enzyme E2 L3 Antibody (YA3303) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ubiquitin Conjugating Enzyme E2 L3.

HY-P83558A

	Ubiquitin Conjugating Enzyme E2 L3 Antibody (YA3303)(PBS only) E2-F1; L-UBC; UBCH7; UbcM4	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Ubiquitin Conjugating Enzyme E2 L3 Antibody (YA3303) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ubiquitin Conjugating Enzyme E2 L3.